Multivariate Analysis as a Method to Evaluate Antigenic Relationships between Bovine Viral Diarrhea Virus 1b Isolates and Vaccine Strains.
antigenicity
bovine viral diarrhea virus
genetic diversity
principal component analysis
virus-neutralizing titer
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
received:
08
09
2023
revised:
09
10
2023
accepted:
10
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The antigenicity of bovine viral diarrhea virus (BVDV) has been evaluated using virus-neutralizing titer data analyzed by principal component analysis (PCA) and has demonstrated numerous isolates to be antigenically divergent from US vaccine strains. The lack of BVDV-1b strains in currently licensed vaccines has raised concerns regarding the lack of protection against BVDV-1b field strains. The aim of this study was to evaluate the antigenic diversity of BVDV-1b strains and better understand the breadth of antigenic relatedness using BVDV-1b antisera and antisera from vaccine strains. Results from this analysis demonstrate the antigenic diversity observed among BVDV-1b isolates and genetic assignment into the BVDV-1b subgenotype is not representative of antigenic relatedness. This is demonstrated by BVDV-1b isolates (2280N, SNc, Illc, MSU, and 2337) observed to be as antigenically dissimilar as BVDV-2a isolates when using BVDV-1b antisera. Additionally, when BVDV-1a vaccine antisera was used for comparisons, a greater percentage of BVDV-1b isolates clustered with BVDV-1a vaccine strains as part of PC1, suggesting antigenic relatedness and potentially partial protection. Collectively, data from this study would suggest that while most BVDV-1b isolates are antigenically similar, there are antigenically dissimilar BVDV-1b isolates as determined by the lack of cross-reactivity, which may contribute to the lack of protection.
Identifiants
pubmed: 37896862
pii: v15102085
doi: 10.3390/v15102085
pmc: PMC10612043
pii:
doi:
Substances chimiques
Vaccines
0
Immune Sera
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
J Vet Diagn Invest. 2010 Mar;22(2):184-91
pubmed: 20224075
J Vet Diagn Invest. 2016 Sep;28(5):519-28
pubmed: 27400958
Vet Res. 2014 Apr 04;45:38
pubmed: 24708266
Vet Microbiol. 2013 Sep 27;166(1-2):242-5
pubmed: 23764273
Virology. 2017 Sep;509:232-238
pubmed: 28668732
Am J Vet Res. 2011 Mar;72(3):367-75
pubmed: 21355740
Vet Microbiol. 1995 Dec;47(3-4):317-29
pubmed: 8748547
Front Vet Sci. 2021 Jun 15;8:685114
pubmed: 34212022
Arch Virol. 1988;99(1-2):117-23
pubmed: 2833200
Virology. 1994 Nov 15;205(1):66-74
pubmed: 7975238
Can J Vet Res. 2009 Oct;73(4):283-91
pubmed: 20046630
J Vet Diagn Invest. 2011 Mar;23(2):185-93
pubmed: 21398436
Virus Res. 1998 Oct;57(2):171-81
pubmed: 9870585
Viruses. 2017 May 26;9(6):
pubmed: 28587150
J Gen Virol. 1988 Jan;69 ( Pt 1):77-86
pubmed: 2447228
Vet Microbiol. 2008 Sep 18;131(1-2):93-102
pubmed: 18424020
Biologicals. 2003 Jun;31(2):89-95
pubmed: 12770537
J Vet Diagn Invest. 2012 Mar;24(2):253-61
pubmed: 22379042
Virology. 2019 Feb;528:19-29
pubmed: 30553108
Vet Microbiol. 2000 Nov 15;77(1-2):145-55
pubmed: 11042408
PLoS One. 2018 Dec 5;13(12):e0207604
pubmed: 30517140
Vaccine. 2010 Dec 10;29(1):70-6
pubmed: 21034829
Vet Microbiol. 2005 Jun 15;108(1-2):13-22
pubmed: 15917132
Can J Vet Res. 2009 Oct;73(4):292-7
pubmed: 20046631
Am J Vet Res. 1995 Jun;56(6):755-9
pubmed: 7653884
Vaccine. 2020 Aug 10;38(36):5764-5772
pubmed: 32690424
Vet Ther. 2006 Spring;7(1):27-34
pubmed: 16598681
BMC Res Notes. 2023 Jun 26;16(1):121
pubmed: 37365644
J Virol Methods. 2022 Jan;299:114328
pubmed: 34710497
J Vet Diagn Invest. 2005 Jan;17(1):10-5
pubmed: 15690945